Small molecule neuropeptide s and melanocortin 4 receptor ligands as potential treatments for substance use disorders

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

There is a vital need for novel approaches and biological targets for drug discovery and development. Treatment strategies for substance use disorders (SUDs) to date have been mostly ineffective other than substitution-like therapeutics. Two such targets are the peptide G-protein-coupled receptors neuropeptide S (NPS) and melanocortin 4 (MC4). Preclinical evidence suggests that antagonists, inverse agonists, or negative allosteric modulators of these receptors might be novel therapeutics for SUDs. NPS is a relatively unexplored receptor with high potential for treating SUD. MC4 has a strong link to early-onset obesity, and emerging evidence suggests significant overlap between food-maintained and drug-maintained behaviors making MC4 an intriguing target for SUD. This chapter provides an overview of the literature in relation to the roles of NPS and MC4 in drug-seeking behaviors and then provides a medicinal chemistry-based survey of the small molecule ligands for each receptor.

Cite

CITATION STYLE

APA

Blough, B., & Namjoshi, O. (2020). Small molecule neuropeptide s and melanocortin 4 receptor ligands as potential treatments for substance use disorders. In Handbook of Experimental Pharmacology (Vol. 258, pp. 61–87). Springer. https://doi.org/10.1007/164_2019_313

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free